Objective: The objective of this paper is to determine whether patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD) possess differential IgM-and IgG-specific reactivity against peptides from the U1 small nuclear ribonucleoprotein particle (U1 snRNP). Methods: The IgM-and IgG-mediated responses against 15 peptides from subunits of the U1 snRNP were assessed by indirect enzyme linked immunosorbent assays (ELISAs) in sera from patients with SLE and MCTD and healthy individuals (n ¼ 81, 41, and 31, respectively). Additionally, 42 laboratory tests and 40 clinical symptoms were evaluated to uncover potential differences. Binomial logistic regression analyses (BLR) were performed to construct models to support the independent nature of SLE and MCTD. Receiver operating characteristic (ROC) curves corroborated the classification power of the models. Results: We analyzed IgM and IgG anti-U1 snRNP titers to classify SLE and MCTD patients. IgG anti-U1 snRNP reactivity segregates SLE and MCTD from nondisease controls with an accuracy of 94.1% while IgM-specific anti-U1 snRNP responses distinguish SLE from MCTD patients with an accuracy of 71.3%. Comparison of the IgG and IgM anti-U1 snRNP approach with clinical tests used for diagnosing SLE and MCTD revealed that our method is the best classification tool of those analyzed (p 0.0001). Conclusions: Our IgM anti-U1 snRNP system along with lab tests and symptoms provide additional molecular and clinical evidence to support the hypothesis that SLE and MCTD may be distinct syndromes. Lupus (2013) 22, 1371-1381.
Introduction
Systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD) are systemic autoimmune disorders with overlapping clinical manifestations that possess aberrant immune responses against common autoantigens.
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Despite its description as an independent autoimmune disease, 7 the classification of MCTD as distinct from SLE remains controversial because of the high number of common clinical features between SLE and MCTD patients. [7] [8] [9] [10] [11] [12] [13] Nevertheless, the concept of MCTD has been reported as a useful definition in clinical practice, 3, [11] [12] [13] and clinical and serological features segregate the two illnesses. [14] [15] [16] The American College of Rheumatology (ACR) has created universal classification parameters for SLE; 14 however, four different criteria sets exist for MCTD patients, with the Alarco´n-Segovia criteria being the most widely accepted.
SLE and MCTD, 2, 4, 15, [18] [19] [20] which has hampered the identification of MCTD as a separate syndrome. A positive diagnosis by any set of criteria requires a patient to exhibit at least four clinical symptoms and/or tests out of those included in each list, which can take years to develop. 2, 14 Moreover, traditional laboratory tests are performed with numerous commercially available kits that can vary in principle and cut-off values, which may alter the final results and diagnoses. 4, 15, 18, 21, 22 These and other factors complicate proper diagnosis of these two closely related and overlapping illnesses.
Previous investigations have demonstrated that SLE and MCTD patients often exhibit 1000-fold greater autoreactivity to subunits of the U1 small nuclear ribonucleoprotein particle (snRNP) than to any other cellular component. 23, 24 The U1 snRNP is an RNA-protein complex that is responsible for pre-mRNA processing and is composed of 10 proteins (U1-70 K, U1A, U1C, and seven Smith antigen (Sm) proteins). [25] [26] [27] [28] In general, previous studies aimed at finding biomarkers for SLE and MCTD have focused on immunoglobulin G (IgG)-specific responses to nuclear components, including the U1 snRNP; however, some studies have revealed differential immunoglobulin M (IgM) reactivity for nuclear components in SLE and MCTD patients. 24, [29] [30] [31] Yet, the potential use of the IgM response as a molecular tool to classify SLE and MCTD patients has not been fully explored.
To determine whether SLE and MCTD represented distinct disorders and to test whether the two patient groups can be segregated, we evaluated the IgG-and IgM-specific responses of patients with SLE and MCTD and healthy individuals against 15 different U1 snRNP peptides (named P1-15) by indirect enzyme-linked immunosorbent assays (ELISAs). Interestingly, we observed higher IgG-based reactivity for U1 snRNP peptides in individuals with SLE or MCTD compared to healthy individuals, but elevated IgM responses in SLE patients compared to those with MCTD and healthy adults. The IgM response to two peptides, P4 and P10 (P4/P10), exhibited 71.3% accuracy in segregating between these two autoimmune disorders (p 0.05). In summary, these data support the notion that SLE and MCTD are, indeed, distinct disorders and highlight the potential clinical use of the IgM anti-U1 snRNP system as a molecular tool to assist in the classification of SLE and MCTD patients.
Methods
Collection and preparation of sample sera Sera were obtained from whole blood of 122 patients previously diagnosed with SLE (n ¼ 81) or MCTD (n ¼ 41) and 31 healthy individuals. Samples were collected following the institutional review board (IRB)-accepted protocols of the University of Miami (IRB numbers: 200307-24 and 200402-86) and Florida International University (IRB number: 040308-00). SLE and MCTD patients (collectively referred to here as ''ill'' or ''patient group'') were clinically diagnosed according to the ACR criteria 14 and the Alarco´n-Segovia criteria, 17 respectively, along with clinician judgment. The laboratory tests in this study were commercially performed by Quest Diagnostic Incorporated, and their positive values are included in Table 1 . Details of the flare or remission period in these SLE and MCTD patients were not recorded at the moment of whole blood collection and, therefore, disease activity for these SLE and MCTD patients has not been considered in this study.
Selection of U1 snRNP peptides
The U1 snRNP peptides included were previously reported in Somarelli et al., 32 and commercially synthesized by BioMatik Corporation (Wilmington, DE, USA). The observed IgM reactivity for each of the U1 snRNP peptides was ranked from most (1) to least (15) antigenic for each disease state (Table 2) .
Monitoring IgM reactivity for U1 snRNP peptides by indirect ELISAs
The indirect ELISA protocol employed to assess IgM reactivity for each peptide and sample included was previously described. 32 The average IgM-derived optical density (OD) value for each peptide was normalized using the average OD value of the healthy group per peptide examined and was expressed as OD% based on the following formula 33 (Supplementary data 1):
OD% ¼ X OD of sample in Px X OD of control group in Px 100
where '' X OD of sample in P x '' is the average OD value of the sample group (SLE or MCTD) and '' X OD of control in P x '' indicates the average OD of the control group (healthy group) from each of the peptides included in this study (P1-P15). To evaluate the relative reactivity contributed by IgM and IgG in SLE, MCTD, and healthy populations, the average OD values from IgG-specific ELISAs previously reported by Somarelli et al., 32 which used the same samples and U1 snRNP peptides included in this study, were re-analyzed and converted to OD% using the equation described above 33 (Supplementary data 2).
Statistical analyses
Significant differences in IgG and IgM reactivity between patient (SLE and MTCD) and healthy groups and between SLE and MCTD individuals for each of the peptides was assessed using independent sample t-tests. Clinical tests and symptoms were evaluated by independent sample t-tests (numerical data) or Chi (X) squared tests (nominal data). Receiver operating characteristic (ROC) indicates that a test for renal hematuria was considered positive when there was no other reason for hematuria, such as infection. SLE: systemic lupus erythematosus; MCTD: mixed connective tissue disease; ELISA: enzyme-linked immunosorbent assay; RF: rheumatoid factor; anti-dsDNA: anti-double-stranded DNA.
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curves were generated with the PASW software package (version 18). Forward binary logistic regression (BLR) analyses using the IgM and IgG anti-U1 snRNP titers in ill (SLE and MCTD) and healthy individuals as well as SLE and MCTD patients were performed with the PASW software package (version 18). P values 0.05 were considered statistically significant for all tests. Correlations between the IgM anti-U1snRNP peptide reactivity and IgM anti-rheumatoid factor (RF) antigenicity were performed using the PASW software package (version 18). We found no significant correlation between the IgM-specific anti-U1 snRNP reactivity and IgM-mediated anti-RF activity. As a result, these analyses were not further considered in this study.
Results

IgM anti-U1 snRNP reactivity is elevated in SLE but not MCTD patients
The IgM response to U1 snRNP peptides was monitored via indirect ELISAs and reported as OD% (Figure 1 (a) and Supplementary data 1). IgM anti-U1 snRNP titers were significantly higher in the SLE group than either the MCTD population or healthy individuals (p 0.05). In fact, in many instances, IgM responses to U1 snRNP peptides in MCTD patients were equal to or below those exhibited by healthy individuals (P3, P4, and P9-P15 in Figure 1(a) ). The discrimination capacity of IgM anti-U1 snRNP peptide ELISAs was assessed by ROC curve analysis and indicates that IgM reactivity for P1 and P13 provides significant power to classify SLE and MCTD patients; however, none of the IgM responses were sufficient to discern SLE and MCTD from nondisease controls with statistical significance (Figure 1(c-d) and Supplementary data 3).
SLE and MCTD patients exhibit an elevated IgG response for U1 snRNP peptides
As previous studies have reported, 32, [34] [35] [36] [37] [38] the IgGmediated reactivity for each of the U1 snRNP peptides was significantly higher both in SLE and MCTD populations than in the healthy group; however, IgG reactivity does not differ between the two autoimmune disorders (Figure 1(b) ). ROC curve analyses on IgG anti-U1 snRNP titers per peptide show their individual ability to discern between patients (SLE and MCTD) and healthy individuals and between SLE and MCTD patients The peptide designation, region and sequences as well as the U1 snRNP protein column displayed in this Differential Ig responses to the U1 snRNP in SLE and MCTD A Mesa et al.
( Figure 1(c-d) , respectively). As previously reported, 32 all but IgG anti-P2 responses were capable of significantly discriminating SLE and MCTD from healthy individuals with IgG anti-P4 being the best (p 0.05); however, none of the IgG anti-U1 snRNP titers had a statistically significant ability to classify SLE and MTCD patients (Figure 1(d) ).
Differential autoimmune responses and symptoms are observed in SLE and MCTD patients
We found that SLE and MCTD patients exhibit significantly different IgM anti-U1 snRNP reactivity (p 0.05) despite similar IgG-mediated antigenicity for the same peptides (Figures 1(ab) ). To further support the idea that SLE and MCTD represent distinct autoimmune illnesses, statistical analysis of 42 standard laboratory tests were performed with blood samples from the SLE and MCTD patient cohort. These analyses revealed that 11 out of the 42 clinical tests were significantly different in SLE and MCTD patients (p 0.05) ( Table 1) . Specifically, differences were observed in tests designed to detect nuclear autoantigens (RNP, Sm, SCL70, dsDNA, elevated DNA), renal function (creatine phosphokinase levels, renal proteinuria, renal hematuria) and immune system components (C3 and C4 complement levels) (p 0.05). These findings support the idea P2  P3  P4  P5  P6  P7  P8  P9  P10  P11  P12  P13  P14  P15  P1  P2  P3  P4  P5  P6  P7  P8  P9  P10  P11  P12  P13  P14 P2  P3  P4  P5  P6  P7  P8  P9  P10  P11  P12  P13  P14  P15  P1  P2  P3  P4  P5  P6  P7  P8  P9  P10  P11  P12  P13  P14 that SLE and MCTD represent distinct autoimmune manifestations, with specific antigenic targets and antibody class reactivities. Similarly, statistical assessment of 40 clinical symptoms from patients in our SLE and MCTD cohort indicated that 16 out of the 40 clinical characteristics evaluated were significantly different between SLE and MCTD patients ( Table 3 ). Most of the significantly different clinical manifestations involved the skin and joints of these patients; however, our data also confirmed that neuropsychiatric disorders and problems in the circulatory system were also significantly different between the two groups. Once again, the fact that clinical symptoms differ in SLE and MCTD populations supports the hypothesis that these maladies may be clinically distinct.
Antibody class reactivities for U1 snRNP peptides segregate among SLE, MCTD, and healthy individuals
The IgM and IgG responses for all U1 snRNP peptides were combined in a BLR to determine which peptide and autoantibody combinations might provide the highest segregation between patient (SLE and MCTD) and healthy populations. These analyses revealed that the combined IgG-specific response for P2, P4, P5, P10, and P13 has the greatest capacity to discern between sick and healthy individuals with an overall accuracy of 94% (p 0.05) (Figure 2(a) ), where the probability of correctly predicting a patient with either SLE or MCTD is higher than that for correctly predicting a healthy individual (96.7% and 83.9%, respectively).
Additional BLRs were performed with the individual IgG and IgM reactivities for each U1 snRNP peptide to assess which peptide and Ig class combination significantly discriminates between SLE and MCTD patients. These analyses indicated that only the combined IgM response for P4 (U1C) and P10 (U1A) significantly discriminate between SLE and MCTD patients, with an overall accuracy of 71.3% (p 0.05) (Figure 2(b) ). Remarkably, most of the classification power derives from the proper classification of SLE patients (95.1%) rather than proper grouping of MCTD patients (24.4%) (Figure 2(b) ). Consequently, our data demonstrate that by first combining the IgG reactivity for P2, P4, P5, and P10 and then the titers for IgM anti-P4/P10, we can achieve an overall accuracy of 73.9% at discriminating among SLE, MCTD, and healthy groups.
Comparing the power of IgM anti-P4/P10 with conventional clinical tests
To determine the classification power of our proposed IgM-specific P4/P10 ELISA-based assay, ROC curves were used to compare our system with eight conventional clinical tests. The individual IgM reactivities for P1 and P13 were also included in the ROC curve analyses because they discriminate between SLE and MCTD (Figure 1(d) ). The 11 laboratory tests that significantly differ between SLE and MCTD patients were performed only in a small portion of each subpopulation ( Table 1) . As a result, not all tests could be analyzed because of the reduced sample size. Instead, eight of the most frequently used laboratory tests that are part of the classification criteria to diagnose SLE or MCTD were included in the ROC curve analysis (FANA titers, dsDNA ELISA, elevated serum DNA titers, and positive results for RNP, Sm, SSA, SSB, and SCL-70). 4, 15, 16, 21, 22 When using the subset of individuals for whom clinical test results were available (SLE ¼ 59 and MCTD ¼ 24), the IgM anti-P4/P10 titers and IgM anti-P1 reactivity displayed the greatest discrimination capacity to classify SLE and MCTD patients (p 0.05) (Figure 3 and Supplementary data 3). ROC curves confirmed that among the conventional tests evaluated, elevated DNA and positive results for Sm are the third and fourth best at significantly segregating SLE and MCTD (p 0.05).
Improving the discriminatory capacity of IgM anti-P4/P10 titers BLR analyses were performed to assess whether the combination of the IgM anti-P4/P10 system and any of the eight laboratory tests employed to diagnose SLE or MCTD (FANA titers, dsDNA ELISA, elevated serum DNA titers and positive results for RNP, Sm, SSA, SSB, and SCL-70) 4, 15, 16, 21, 22 might provide greater capacity to distinguish between these syndromes. The individual IgM reactivities for P1 and P13 were considered in this BLR analysis because they showed a significant ability to classify SLE and MCTD patients (p 0.05) (Figure 1(d) ). BLR analyses indicated that the combination of the IgM-based reactivity for P4/P10 and an elevated DNA assay represent the best combination of variables to segregate SLE from MCTD when compared with IgM anti-P4/P10, -P1, or-P13 and any single laboratory test examined (p 0.0001) (Figure 3 and Supplementary data 3). None of the other clinical test combinations improved the power of Differential Ig responses to the U1 snRNP in SLE and MCTD A Mesa et al. discrimination between SLE and MCTD patients over that exhibited by the individual tests alone (p 0.05). Our analyses also suggest that, when combined with the standard elevated DNA test, the IgM response against P4/P10 may be useful in enhancing the current segregation of SLE from MCTD.
Discussion
Despite the fact that MCTD was described as a distinct rheumatic syndrome in 1972, 7 placement of this disorder as a separate autoimmune illness remains controversial. Opinions are divided regarding classification of MCTD as a separate malady because of the number of autoantigens and clinical symptoms that show overlap with SLE. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The immune responses of SLE and MCTD patients for overlapping ''self'' antigens coupled with the diversity of commercially available clinical tests with differing protocols, reagents, and cut-off values have impeded the development of standard and uniform assays to segregate these syndromes. 2, 4, 6, 21 With the exception of a few studies, 24, [29] [30] [31] most investigations have focused on IgG-mediated reactivity toward specific antigens as potential molecular tools to differentiate between SLE and MCTD patients. [34] [35] [36] [37] [38] Given that SLE and MCTD patients are characterized by elevated blood titers of multiple Ig classes, including IgM, 26, [39] [40] [41] [42] we hypothesized that IgM responses to a number of U1 snRNP peptides may allow us to increase the present discrimination between SLE and MCTD and provide additional molecular evidence to claim the independent nature of these two disorders.
Our data indicate that the combined IgM reactivity for fragments of U1C (P4) and U1A (P10) is capable of classifying SLE and MCTD patients with an accuracy of 71.3% (Figure 2(b) ), a value higher than previously reported peptidebased immunoassays that have been used to segregate these disorders. 21 These findings are in concordance with previous reports, which revealed a preponderance of IgM anti-U1 snRNP antibodies in SLE, but not MCTD patients. 24, 30 Therefore, our work is congruent with prior investigations and demonstrates the potential utility of differential Ig class responses as a classification tool for SLE and MCTD. The current work also provides molecular evidence to support the distinct etiology of these syndromes. The binomial analyses identified combinations of laboratory tests and/or peptide reactivities that significantly discern between these maladies. Interestingly, the IgM anti-P4/P10 ELISA-based system provided the greatest capacity to segregate between SLE and MCTD disorders over eight other conventional laboratory tests (p 0.0001) (Figure 3) . Additionally, we revealed that the combination of IgM anti-P4/P10 antigenicity with the elevated DNA test segregated 79.8% of SLE and MCTD patients, even in the smaller subset of patients for whom clinical test results were available (n ¼ 59 for SLE and n ¼ 24 for MCTD) (Figure 3) . It is not surprising that the dsDNA test contributes to the differentiation of these diseases given that antibodies against DNA have been detected in approximately 70% of SLE patients and shows 95% specificity for this disorder. 16 ,18 Yet, the fact that the dsDNA test alone exhibits a lower ability to segregate SLE and MCTD patients (66.4%) than the IgM anti-P4/P10 system (73.1%) indicates the significant contribution of our ELISAbased system in discerning between these two maladies ( Figure 3 ). We delineated a total of 16 out of 40 clinical manifestations that differed significantly between SLE and MCTD patients (Table 3 ). On average, MCTD patients exhibited hand/joint swelling and muscle weakness with 25% higher frequency than SLE patients. Similarly, malar and discoid rashes were found to be more prevalent in the SLE than the MCTD group (46% and 10% versus 13% and 0%, respectively). These findings are in concordance with previous studies that reported these clinical manifestations as key features in SLE or MCTD patients. 19, 20 Evidence of mental illness was also found to be 32% higher in MCTD than SLE patients. Although we cannot rule out selection bias of the clinicians diagnosing these disorders, our results obtained from a subset of SLE and MCTD patients suggest that the immune response of SLE patients seems to be directed to skin areas on the face while those suffering from MCTD appear to develop a more systemic immune response that attacks the skin, joints, and muscles throughout various parts of the body. Furthermore, these findings highlight specific clinical manifestations that appear to differ between SLE and MCTD patients and should be considered as clinical evidence that they may be distinct diseases.
Overall, this study further highlights the current challenges in developing quantitative tests for the classification of SLE and MCTD and therefore the recognition of MCTD as a separate entity. 4, 2, 6, 21 Here, we describe a novel approach based on differential antibody class (IgM and IgG) responses as a mechanism to discriminate between SLE and MCTD patients with better accuracy than conventional laboratory tests currently employed as part of the classification criteria to diagnose these syndromes. In addition, our data revealed contrasting frequencies of clinical symptoms characterizing these autoimmune syndromes whereby SLE patients showed a concentrated autoimmune manifestation directed to skin areas on the face while those suffering from MCTD developed more systemic immune responses that attack the skin, joints, and muscles throughout various parts of the body. Consequently, our results provide further evidence to support the fact that there are molecular and clinical aspects of SLE and MCTD to indicate that these diseases are, indeed, two distinct autoimmune syndromes.
